Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
11/8/25 Amgen (AMGN) Repatha for Dyslipidemia / Hypercholesterolemia Subscribers Only Subscribers Only Subscribers Only
11/7/25 AstraZeneca (AZN) Fasenra for Hypereosinophilic Syndrome (HES) Subscribers Only Subscribers Only Subscribers Only
11/6/25 Bayer (BAYN) Kerendia for Diabetic Nephropathy Subscribers Only Subscribers Only Subscribers Only
11/6/25 Noema NOE-115 for Menopause (including Hormone Replacement Therapy [HRT]) Subscribers Only Subscribers Only Subscribers Only
11/6/25 Eledon Pharmaceuticals (ELDN) tegoprubart for Kidney Transplant Rejection Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
01/31/2025 Subscribers Only Subscribers Only Trial Announcement - Initiation
01/31/2025 Subscribers Only Subscribers Only Trial Announcement - Initiation
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/26/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update